611 related articles for article (PubMed ID: 17442198)
1. Sirolimus-eluting cobalt alloyed stents in treating patients with coronary artery disease: six-month angiographic and one-year clinical follow-up result. A prospective, historically controlled, multi-center clinical study.
Zhang Q; Xu B; Yang YJ; Zhang RY; Li JP; Qiao SB; Zhang JS; Hu J; Qin XW; Hong T; Chen JL; Huo Y; Shen WF; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):533-8. PubMed ID: 17442198
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent.
Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF
Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131
[TBL] [Abstract][Full Text] [Related]
3. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
4. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
[TBL] [Abstract][Full Text] [Related]
5. Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction.
Gao H; Yan HB; Zhu XL; Li N; Ai H; Wang J; Li SY; Yang D
Chin Med J (Engl); 2007 May; 120(10):863-7. PubMed ID: 17543174
[TBL] [Abstract][Full Text] [Related]
6. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Firebird sirolimus-eluting stent in treatment of complex coronary lesions in Chinese patients: one-year clinical and eight-month angiographic outcomes from the FIREMAN registry.
Li Y; Li CX; Wang HC; Xu B; Fang WY; Ge JB; Wang WM; Qiao SB; Chen JP; Shen WK; Jiang H; Cong HL; Pu XQ; Qin YW; Jin HG; Cao Y; Huang H
Chin Med J (Engl); 2011 Mar; 124(6):817-24. PubMed ID: 21518586
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the firebird sirololimus eluting stent in all comers with coronary artery stenosis.
Tresukosol D; Pornratanarangsi S; Chotinaiwattarakul C; Tungsubutra W; Phankingthongkum R; Wongpraparut N; Lirdwilai T; Dapang T; Panchavinnin P
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S11-20. PubMed ID: 20364552
[TBL] [Abstract][Full Text] [Related]
9. Age-based clinical and angiographic outcomes after sirolimus-eluting stent implantation in patients with coronary artery disease.
Xu B; Li JJ; Yang YJ; Chen JL; Qiao SB; Qin XW; Ma WH; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
Chin Med J (Engl); 2007 Mar; 120(6):447-51. PubMed ID: 17439734
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years.
Zhang Q; Xu B; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Chen JL; Shen WF; Gao RL
Chin Med J (Engl); 2008 Sep; 121(17):1670-4. PubMed ID: 19024097
[TBL] [Abstract][Full Text] [Related]
12. [Intravascular ultrasound evaluation on the efficacy of national made Firebird stents comparing with Cypher stents].
DU R; Zhang RY; Zhu ZB; Zhang Q; Hu J; Zhang JS; Shen WF
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Feb; 38(2):121-5. PubMed ID: 20398556
[TBL] [Abstract][Full Text] [Related]
13. Six-month clinical outcomes of Firebird 2TM sirolimus-eluting stent implantation in real-world patients with coronary artery diseases.
Ge JB; Zhang F; Qian JY; Ge L; Liu XB; Zhou J
Chin Med J (Engl); 2011 Mar; 124(6):831-5. PubMed ID: 21518588
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT).
Thuesen L; Kelbaek H; Kløvgaard L; Helqvist S; Jørgensen E; Aljabbari S; Krusell LR; Jensen GV; Bøtker HE; Saunamäki K; Lassen JF; van Weert A;
Am Heart J; 2006 Dec; 152(6):1140-5. PubMed ID: 17161067
[TBL] [Abstract][Full Text] [Related]
15. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxcel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study.
Fischer D; Scheller B; Schäfer A; Klein G; Böhm M; Clever Y; Cremers B
EuroIntervention; 2012 Aug; 8(4):450-5. PubMed ID: 22917728
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
[TBL] [Abstract][Full Text] [Related]
18. [Effects of sirolimus-eluting stent and the paclitaxel-eluting stent: a three-year follow-up study].
Gao Z; Yang YJ; Chen JL; Qiao SB; Xu B; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Li JJ; Gao RL
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1811-4. PubMed ID: 19040014
[TBL] [Abstract][Full Text] [Related]
19. Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial.
Yuan F; Chen X; Song X; Wang D; Zhang Z; Li W; Li Z; Li H; Chen X; Huo Y; Wang L; Lu C; Lu Q; Xu B; Li W; Lyu S;
Chin Med J (Engl); 2014; 127(14):2561-6. PubMed ID: 25043067
[TBL] [Abstract][Full Text] [Related]
20. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Roy P; Steinberg DH; Sushinsky SJ; Okabe T; Pinto Slottow TL; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Weissman NJ; Lindsay J; Waksman R
Eur Heart J; 2008 Aug; 29(15):1851-7. PubMed ID: 18550555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
